PLoS ONE (Jan 2022)

Adalimumab biosimilars in the therapy of Crohn´s disease and ulcerative colitis: Prospective multicentric clinical monitoring.

  • Martin Wasserbauer,
  • Stepan Hlava,
  • Jiri Drabek,
  • Jan Stovicek,
  • Petra Minarikova,
  • Lenka Nedbalova,
  • Tomas Drasar,
  • Zdena Zadorova,
  • Jiri Dolina,
  • Stefan Konecny,
  • Vladimír Kojecky,
  • Jana Kozeluhova,
  • Pavlina Cernikova,
  • Dita Pichlerova,
  • Barbora Kucerova,
  • Stepan Coufal,
  • Radan Keil

DOI
https://doi.org/10.1371/journal.pone.0271299
Journal volume & issue
Vol. 17, no. 8
p. e0271299

Abstract

Read online

ObjectiveThe adalimumab biosimilars FKB327 and GP2017 were approved for the therapy of patients with inflammatory bowel disease (IBD). Relatively few prospective studies with biosimilar adalimumab in patients with IBD have been published. The aim of this prospective observational study was to evaluate the effectiveness and safety of the biosimilar adalimumab.Material and methodsAdalimumab biosimilars FKB327 (Hulio®) and GP2017 (Hyrimoz®) were indicated to 50 naive patients in terms of biological therapy with Crohn's disease (CD) or ulcerative colitis (UC). Effectiveness of therapy was evaluated via the Crohn's Disease Activity Index [CDAI] or the Mayo Scoring System [MSS] in patients with CD or UC, respectively, before and after 12 weeks. Additional goals were to evaluate weight changes, laboratory tests and complications or adverse events of this therapy.ResultsIn CD patients, remission (CDAI ConclusionsThis prospective observational study proved the effectiveness of the adalimumab biosimilars FKB327 and GP2017 in IBD.